Kodiak Sciences Inc, RemeGen, Vantage Biosciences Ltd, Apexian Pharmaceuticals, Ocular Therapeutix, Regenxbio, Adverum Biotechnologies, and Therini Bio Pty Ltd. have actively advanced innovative therapies aimed at addressing unmet clinical needs and improving long-term patient outcomes in Diabetic Retinopathy (DR). DelveInsight's latest report, ?Diabetic Retinopathy Pipeline Insight, 2026,? offers comprehensive insights into more than 50 companies and over 55 pipeline drugs shaping the future of the Diabetic Retinopathy treatment landscape.
The report provides a detailed evaluation of pipeline drug profiles across clinical and nonclinical stages, along with an extensive therapeutic assessment based on product type, development stage, route of administration, and molecule type. Additionally, it highlights inactive and discontinued programs, offering a holistic view of the evolving pipeline ecosystem. Diabetic Retinopathy is a serious microvascular complication of diabetes that affects the retina, the light-sensitive tissue located at the back of the eye.
It arises due to prolonged hyperglycemia, which damages retinal blood vessels, leading to leakage, swelling, and abnormal blood vessel growth. The pathophysiology of Diabetic Retinopathy is complex and multifactorial. Chronic hyperglycemia activates several biochemical pathways, including the polyol pathway and protein kinase C pathway, while simultaneously increasing oxidative stress and inflammatory responses.
Elevated levels of vascular endothelial growth factor (VEGF) play a critical role in promoting abnormal angiogenesis and vascular permeability. Diagnosis and monitoring of DR rely on advanced ophthalmic imaging techniques. Optical Coherence Tomography (OCT) enables high-resolution visualization of retinal thickness and macular swelling, while fluorescein angiography and OCT angiography provide insights into retinal vascular integrity and blood flow abnormalities.
Current treatment strategies primarily focus on slowing disease progression and managing symptoms. Anti-VEGF therapies such as Avastin, Eylea, and Lucentis are widely used to reduce macular edema and inhibit abnormal blood vessel growth. Corticosteroid injections, laser photocoagulation, and vitrectomy surgery are also employed in advanced cases. The Diabetic Retinopathy pipeline is witnessing rapid innovation, with a growing emphasis on novel mechanisms of action, sustained drug delivery systems, and disease-modifying therapies.
Advances in molecular biology, gene therapy, and ocular drug delivery technologies are reshaping the treatment paradigm. The report highlights that more than 50 companies are actively engaged in developing therapies targeting key pathological drivers such as VEGF signaling, inflammation, fibrosis, and neurodegeneration. The pipeline includes a diverse array of therapeutic modalities, ranging from monoclonal antibodies and small molecules to gene therapies and recombinant fusion proteins.
A key trend shaping the pipeline is the development of long-acting and sustained-release formulations aimed at reducing treatment burden and improving patient adherence. Gene therapy approaches are gaining traction as potential one-time treatments that could provide long-lasting therapeutic effects. The pipeline includes over 55 active therapeutic candidates across multiple stages of development.
Increasing focus on long-acting anti-VEGF therapies and sustained delivery platforms. Growing interest in gene therapy as a potential curative approach. Emergence of inflammation-targeting and neuroprotective strategies. Strong collaboration trends across academia and industry players.
Expanding clinical trial activity across global regions. Diverse molecule types including biologics, small molecules, and gene therapies. Continued efforts to address unmet needs such as treatment durability and patient compliance.
In March 2026, Kodiak Sciences Inc. announced positive topline results in the GLOW2 Phase 3 superiority study of Zenkuda for the treatment of patients with diabetic retinopathy. Zenkuda (tarcocimab tedromer) is an anti-vascular endothelial growth factor (VEGF) intravitreal biologic built on Kodiak's proprietary antibody biopolymer conjugate (ABC®) platform. In January 2026, Boehringer Ingelheim initiated a clinical study to evaluate the efficacy of BI 764524 in individuals with diabetic retinopathy, while also determining an optimal treatment regimen for the investigational therapy.
Participants are randomly assigned to one of five study groups. Those in Groups 1, 2, and 3 receive BI 764524 administered as intravitreal injections into one eye. Over a one-year period, participants receive varying numbers of injections at the same dose.
At certain visits, a sham procedure-mimicking an eye injection without the use of a needle-is performed to maintain masking, ensuring participants remain unaware of the number of active injections received. In January 2026, Invirsa Inc. announced a Phase 2 clinical study designed to assess the efficacy of topically administered INV-102 eye drops. The study evaluates a 12-week dosing regimen in subjects with non-center-involved diabetic macular edema (NCIDME) associated with non-proliferative diabetic retinopathy (NPDR) in Part 1, and an 8-week dosing regimen in subjects with center-involved diabetic macular edema (CIDME) associated with NPDR in Part 2. In June 2025, Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.
Tarcocimab tedromer is a next-generation anti-VEGF therapy developed using Kodiak Sciences' proprietary Antibody Biopolymer Conjugate (ABC) platform. Designed for extended durability, the therapy aims to maintain therapeutic drug levels in ocular tissues for prolonged periods, potentially reducing injection frequency. Currently in Phase III clinical trials, tarcocimab represents a significant advancement in improving treatment adherence and long-term outcomes.
VX-01 is an innovative oral therapy targeting AOC-3 inhibition within the neurovascular unit. Unlike conventional therapies, VX-01 is designed to penetrate the blood-retina barrier effectively, ensuring sustained therapeutic activity within ocular tissues. Currently in Phase II development, it offers a novel systemic approach to treating diabetic retinopathy.
